COMPOUNDS HAVING PHARMACOLOGICAL PROPERTIES

摘要

1,265,086. o-Aminoalkyl oximes. PHILIPS GLOEILAMPENFABRIEKEN N.V. 15 July, 1969 [18 July, 1968], No. 35554/69. Heading C2C. Novel oxime ethers of Formula I in which A and B together form a benzo group, in which case R1 is H or CH 3 , R is H or an alkyl group containing from 1 to 5 carbon atoms, and X is O, NH or S, or A and B each represent a hydrogen atom, a methyl group or a halogen atom (Cl, Br or I), in which case X is S, R1 is H, a halogen atom (Cl, Br or I) or CH 3 , and R is H, an alkyl group containing from 1 to 5 carbon atoms, a cycloalkyl group containing from 3 to 6 carbon atoms, or a phenyl, m- or p-chlorophenyl, 3,4-dichlorophenyl, thienyl-2 or 5- chlorothienyl-2 group, whilst, when A and B each represent a hydrogen atom and X is a sulphur atom, R and R1 may also together represent a trimethylene group in which case R1 is bound at the position 2, or an ortho-phenylene or thienylene-2,3 group, in which case R1 is bound at the position 3, and pharmaceutically acceptable acid addition salts, are prepared by (a) reacting a compound of Formula II in which M is a hydrogen or alkali metal atom, with a compound of formula (or a salt thereof) in which Z is halogen or tosyloxy and Y is H or acyl and, when Y is acyl, hydrolysing the product to remove the acyl group, or (b) reacting a compound of Formula III with a compound of formula or (c) reacting a compound of Formula IV in which Z is halogen or tosyloxy, with ammonia. o - (2 - Bromoethyl) - 2 - hexanoylthiopheneoxime is prepared by reacting 2-hexanoylthiopheneoxime with 1,2-dibromoethane. Pharmaceutical compositions having central nervous system activity, for oral or parenteral administration, comprise a compound of Formula I together with a pharmaceutical carrier.